Vanda Pharmaceuticals

VNDAApproved

Washington DC, United StatesFounded 2003vandapharma.com

Founded in 2003 and publicly traded on NASDAQ (VNDA), Vanda Pharmaceuticals leverages genetics and genomics to inform drug discovery and development. The company has achieved significant milestones with FDA approvals for Fanapt® (2009) and HETLIOZ® (2014), and continues to expand its pipeline with late-stage candidates like tradipitant and imsidolimab. Vanda's strategic focus combines commercial execution with a science-driven approach to address complex disorders in circadian rhythms, psychiatry, and inflammation.

Market Cap

$417.9M

Founded

2003

Focus

Small Molecules

VNDA · Stock Price

USD 7.074.39 (-38.31%)

Historical price data

AI Company Overview

Technology Platform

Utilizes genetics, genomics, and pharmacogenetics to inform drug discovery, clinical trial design, and commercial positioning, aiming to identify genetic factors that enhance therapeutic efficacy and safety.

Pipeline Snapshot

77 drugs in pipeline, 31 in Phase 3

Drug	Indication	Stage
Iloperidone	Schizophrenia	Approved
tasimelteon 20 mg capsule + tasimelteon 2 mg I.V.	Non-24-Hour-Sleep-Wake Disorder	Approved
Tradipitant + Placebo + Open Label Tradipitant	Idiopathic Gastroparesis	Phase 3
Imsidolimab	Generalized Pustular Psoriasis	Phase 3
Iloperidone + Placebo	Schizophrenia	Phase 3

Funding History

Total raised: $80M

IPO$50MUndisclosedApr 27, 2006

Series B$20MUndisclosedJun 15, 2004

Series A$10MUndisclosedJan 15, 2003

FDA Approved Drugs

PONVORYNDAMar 18, 2021

HETLIOZ LQNDADec 1, 2020

HETLIOZNDAJan 31, 2014

Opportunities

Significant near-term opportunities include the commercial launch of newly approved BYSANTI™, potential FDA approval and market expansion for HETLIOZ® into the large Jet Lag Disorder market, and the approval of imsidolimab for generalized pustular psoriasis.

Lifecycle management of existing products through new formulations and indications provides additional growth avenues.

Risk Factors

Key risks include regulatory setbacks for late-stage pipeline candidates, challenging commercialization against larger competitors, potential generic competition for core products, and the inherent uncertainty of clinical trial outcomes.

The company's concentrated pipeline and reliance on a few key assets also present financial and operational risks.

Competitive Landscape

Vanda competes with large pharmaceutical companies in psychiatry (e.g., Johnson & Johnson, Otsuka) and immunology, and faces potential competition in circadian disorders. Its differentiation is based on a targeted, genetics-informed development strategy and first-in-class/movel mechanism assets like HETLIOZ® and BYSANTI™, but it must navigate markets dominated by players with greater commercial scale.

Publications

Patents

Pipeline

FDA Approvals